

## Curriculum Vitae

### Sara Pilotto, M.D., Ph.D.

Associate Professor in Medical Oncology, Department of Engineering for Innovation Medicine, University of Verona - P. le L.A. Scuro 10, 37134, Verona (Italy)

### Personal Data

Year of birth: 1985

CF: PLTSRA85D64F918Q

Business address: Medical Oncology, Department of Engineering for Innovation Medicine, University of Verona - P. le L.A. Scuro 10, 37134, Verona (Italy)

E-mail: sara.pilotto@univr.it

Nationality: Italian

Languages:

- Italian (mother tongue)
- English (good reading, spoken and written)
- Spanish (good reading, spoken and written)

### Education and Professional Experience

- 2003/4 – 2008/9: Degree course in Medicine and Surgery at University of Verona (Italy)
  - 2007 – 2009: Internal Student in Medical Oncology, University of Verona (Italy), Director Prof. Gianluigi Cetto.
  - March - October 2009: Pre-doctoral Fellow at Department of Immunology (Director Prof. M. Colombatti), University of Verona. Experiences in molecular biology, cell cultures, *in vivo* models (xenografts).
  - October 15, 2009: Degree in Medicine and Surgery with Full Marks and Honors (110/110 cum laude) at University of Verona (Italy). Experimental thesis: *PSMA (prostate specific membrane antigen) e mesotelina: approcci innovativi di immunotargeting in neoplasia solide umane*. Chairman: Prof. Gianluigi Cetto.
- February 2010: Italian Medical License Exam (IMLE) at University of Verona (Italy)
- From May 2010 to May 2015: Medical Oncology Residency in Medical Oncology, University of Verona (Italy), Director Prof. Giampaolo Tortora.
  - June 10, 2015: Specialistic Degree in Medical Oncology with Full Marks and Honors (70/70 cum laude) at University of Verona (Italy). Experimental thesis: *Molecular characterization of advanced EGFR mutant lung adenocarcinoma with Next-Generation Sequencing and Digital PCR: correlation with activity and efficacy of gefitinib*. Chairman: Prof. Giampaolo Tortora.
- From April 2015 to February 2016: professional experience at the Instituto Oncologico Dr. Rosell - Hospital Universitario Quiron Dexeus (Barcelona) about the preclinical and translational aspects of lung cancer research.
- From October 2015 to October 2018: PhD program in Inflammation, Immunity and Cancer. Project title: *Genetic, epigenetic and micro-environmental markers as predictors of prognosis, response and resistance to chemotherapy, targeted agents and immunotherapy in resected squamous cell lung carcinoma*.
  - May 22, 2019: PhD in Inflammation, Immunity and Cancer at University of Verona (Italy)
- From December 2016 to November 2019: Academic Researcher in Medical Oncology (University of Verona)
- From November 2019 to November 2022: Assistant Professor in Medical Oncology (University of Verona)
- From November 2022: Associate Professor in Medical Oncology (University of Verona)
- From November 2023: Director of the Residency Program in Medical Oncology (University of Verona)

National Scientific qualification as full professor in the Italian higher education system, in the call 2021/2023 (Ministerial Decree n. 553/2021 and 589/2021) for the disciplinary field of 06/D3 - Blood diseases, oncology and rheumatology. (Academic Recruitment Field 06/D - Medical specialities, according to the national classification) [Validity: 17/12/2023 - 17/12/2034].

## Personal Skills and Competences

### **Research Activity and Bibliometric Indicators**

212 peer reviewed articles (PubMed - Scopus) and 1 book chapter.

H-index: 34 (Scopus)

Total citations: 4,312 (Source: Scopus)

Link Scopus: <https://www.scopus.com/authid/detail.uri?authorId=54879746600>

### **Main Areas of Research**

- Comprehensive approach to cancer patients, with a specific focus on nutrition, physical activity and psychological aspects.
- Translational research in the context of lung cancer, particularly exploring the mechanisms of sensitivity/resistance to chemotherapy, targeted therapy and immunotherapy.
- Methodology of clinical trials in both the clinical and the translational setting.
- Clinical research particularly in the context of lung cancer, participating to the clinical development of different agents in phase I, II, III and IV clinical trials (as principal investigator or sub-investigator).
- Building and validation of prognostic/predictive models integrating clinical and genomic/immunological biomarkers.

### **Academic Appointments**

- 2016 – present: Professor for teaching activities in Clinical approach to cancer patient (elective course) - Combined Bachelor's + Master's degree in Medicine and Surgery, University of Verona (Italy)
- 2016 – present: Professor for teaching activities in Medical Oncology - Postgraduate Specialisation in Medical Oncology, University of Verona (Italy)
- 2017 – present: Professor for teaching activities in Assessment and symptoms management in palliative care (Advanced methods of assessment, prevention and assistance to the family and to the communities) - Master's degree in Nursing and Obstetrics, University of Verona (Italy)
- 2018 – present: Professor for teaching activities in Medical Oncology (Clinical nursing care in medical area) - Bachelor's degree in Nursing, University of Verona (Italy)
- 2019 – present: Coordinator of the course Clinical nursing care in medical area - Bachelor's degree in Nursing, University of Verona (Italy)
- 2020 – present: Professor for teaching activities in Opportunities and challenges of new therapies in lung cancer - PhD program in Inflammation, Immunity and Cancer, University of Verona (Italy)
- 2023 – present: Director of the Residency Program in Medical Oncology (University of Verona)

### **Research Projects**

- P.I. in the Italian Association for Cancer Research (AIRC), Investigator Grant Next Gen Clinician Scientist 2023 n° 30204: *A personaliZed nuTrition and physiCAl exerCise intervention to enhance early-stage NSCLC ouTcomes: the STARLight study.*
- Collaborator/Responsible UO3 - Bando di Ricerca Finalizzata 2021 RF-2021-12374037 - Titolo: *A Multiomic Approach to Identify Prognostic and Predictive Signatures in Advanced Non-Oncogene Addicted Non-Small Cell Lung Cancer (NSCLC) receiving Immunotherapy.*

- Co-investigator in the Italian Association for Cancer Research (AIRC), Investigator Grant 2017 n° 20583: *RICTOR/mTOR and FGFR/FRS2 as drivers of prognosis and potential therapeutic targets in squamous cell lung cancer.* P.I. Prof. Emilio Bria
- Cariverona Project 2018: *Analysis and characterization of myeloid cells in solid and hematologic malignancies.* Coordinator Prof. Vincenzo Bronte
- Cariverona Project 2015.0872: *Predictive and diagnostic biomarkers in neoplastic, inflammatory and neurodegenerative diseases.* Coordinator Prof. Giampaolo Tortora
- Co-investigator in the Italian Association for Cancer Research (AIRC), My First AIRC Grant 2013 n° 14282: *Prognostic relevance of potentially druggable driving molecular pathways for resected squamous cell lung carcinoma.* P.I. Prof. Emilio Bria

#### **Prizes and Awards**

- 2015 - Winner of the International Association for the Study of Lung Cancer (IASLC) Fellowship Award. Project title: *Immune checkpoint inhibitor and driving gene mutations as outcome predictors for resected squamous cell lung carcinoma.*

#### **Presentations in Congresses**

Several abstracts and posters presented at international and national oncology meeting.

Speaker in more than 120 national and international congresses. Among them:

- 2023 ESMO 2023 20-24 October – Madrid (Spain). Young Oncologists session: *YO Boxing Session. Do you need a basic science rotation for your career in oncology? - No*
- 2022 World Conference on Lung Cancer (WCLC) 6-9 august 2022 – Vienna (Austria). Educational session: *Is Cytotoxic Chemotherapy in NSCLC Management Only Palliative?* Title: *Second-Line Chemotherapy Following First-Line Mono-Immunotherapy in High PD-L1 (TPS≥50%) Advanced/Metastatic NSCLC.*
- IASLC World Conference on Lung Cancer 2019 Invited Discussant MA07 - *Clinical Questions and Potential Blood Markers For Immunotherapy.* Barcelona, September 7 - 10, 2019
- IASLC World Conference on Lung Cancer 2017 MA.01 SCLC - Research Perspectives. *Lanreotide Maintenance in SCLC Expressing Somatostatine Receptors: Efficacy Results of Multicenter Randomized G04.2011 Trial.* Tokyo, October 15 - 18 2017
- IASLC World Conference on Lung Cancer 2016 OA06.06 - *Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC).* Vienna December 4 - 7 2016
- 11<sup>th</sup> Congress on Lung Cancer by SLCG (Spanish Lung Cancer Group). Barcelona, November 26 - 27 2015

#### **Expert Panel Member**

- 2025 – present: member of the Multidisciplinary Clinical Science Committee of the International Association for the Study of Lung Cancer (IASLC).
- 2019 – present: member of Lung cancer Guidelines Experts Panel of Italian Association of Medical Oncology (AIOM).
- 2021 – present: ESMO faculty member for the Non-Metastatic NSCLC and other Thoracic Malignancies faculty group.
- 2022 – 2023: member of Comitato Etico per le Sperimentazioni Cliniche (CESC) of Istituto Oncologico Veneto IRCCS.
- 2019: Reviewer Projects and/or Research Grants for IASLC (International Association for the Study of Lung Cancer).
- 2019 – 2022: ESMO faculty member for the ESMO Press & Media Affairs Committee.
- IASLC 2020 WCLC - Program Committee Member.
- Member of the ESMO Leadership Program 2019.
- 2015 – present: member of the EORTC Lung Cancer Young Investigator.

### ***Editorial Activity***

Reviewer for several Peer-Reviewed journals:

BMJ, Lancet Respiratory Medicine, Cancer Treatment Reviews, Critical Reviews in Oncology/Haematology, Journal of ImmunoTherapy of Cancer, Therapeutic Advances in Medical Oncology, Immunotherapy, Expert Opinion on Biological Therapy, Targeted Oncology, Plos One, The International Journal of Biological Markers, Translational Lung Cancer Research, Tumori Journal, Cancer Medicine, BMJ Open, BMC Immunology, Lung Cancer, Expert Review of Anticancer Therapy, Oncoimmunology.

- 2020 – present: Editorial Board Member of Frontiers in Oncology for “Thoracic Oncology” specialty section as Associate Editor.
- 2021 – present: Editorial Board Member of Expert Review of Anticancer Therapy.

01/07/2025

A handwritten signature in black ink, appearing to read "R. R. Rao".